Formulation Development Outsourcing Market (By Service: Preformulation, Formulation Development; By Formulation: Topical, Oral, Injectable, Others; By Therapeutic Area: Oncology, Infectious Disease, Respiratory, Cardiovascular, Neurology, Hematology, Dermatology, Others; By End-User: Pharmaceutical Industries, Research and Academic Institutions) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market 

5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Formulation Development Outsourcing Market, By Service

8.1. Formulation Development Outsourcing Market, by Service, 2023-2032

8.1.1. Preformulation

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Formulation Development

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Formulation Development Outsourcing Market, By Formulation

9.1. Formulation Development Outsourcing Market, by Formulation, 2023-2032

9.1.1. Topical

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Oral

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Injectable

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Formulation Development Outsourcing Market, By Therapeutic Area 

10.1. Formulation Development Outsourcing Market, by Therapeutic Area, 2023-2032

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Infectious Disease

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Respiratory

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Cardiovascular

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Neurology

10.1.5.1. Market Revenue and Forecast (2020-2032)

10.1.6. Hematology

10.1.6.1. Market Revenue and Forecast (2020-2032)

10.1.7. Dermatology

10.1.7.1. Market Revenue and Forecast (2020-2032)

10.1.8. Others

10.1.8.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Formulation Development Outsourcing Market, By End-User 

11.1. Formulation Development Outsourcing Market, by End-User, 2023-2032

11.1.1. Pharmaceutical Industries

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Research and Academic Institutions

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.4. Market Revenue and Forecast, by End-User (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)

Chapter 13. Company Profiles

13.1. SGS S.A.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Eurofins Scientific SE

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Element

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Labcorp

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Thermo Fisher Scientific, Inc. (Patheon)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Intertek Group plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Recipharm

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Lonza

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Charles River Laboratories International, Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Catalent Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample